On December 7, 2025, Lyell Immunopharma presented new clinical trial data at the ASH Annual Meeting, showing that their CAR T-cell therapy, ronde-cel, achieved a 93% overall response rate in patients with large B-cell lymphoma after 12 months. The safety profile was manageable, with low rates of serious side effects reported.